undamentalytics Newsletter

Xtant Medical Holdings, Inc. valuation and forecast

Explore the models for Xtant Medical Holdings, Inc., adjust their assumptions and compare your own valuation with the platform's.

Your valuation workspace

What is XTNT worth to you?

Start with the company's financial data. Make the assumptions your own.

5 models available

01 / Assumptions

Follow the forecast

The cash flows behind your value

USD per share
View annual figures
Forecast yearCash flow / share

Negative cash flows are shown in terracotta. Before the terminal value and equity bridge. Residual-income models show excess earnings; dividend models show dividends.

See the range of possibilities

Compare and combine your models

Your weighted value—

Weights start with the platform's included models. Change them to build your own combination. Select a model name to edit its assumptions.

ModelYour value / shareWeight

The platform's price and consistency filters are not reapplied to your scenarios.

Other model types 17 unavailable for XTNT

Price-to-earnings vs peers

no positive earnings in the latest twelve months

Justified price-to-book

return on equity is not positive

Cash-flow DCF

This model does not apply to this company with the available financial data.

P/B vs return on equity

This model does not apply to this company with the available financial data.

Peer price-to-book

This model does not apply to this company with the available financial data.

Peer price-to-FFO

This model does not apply to this company with the available financial data.

Peer price-to-sales

This model does not apply to this company with the available financial data.

Forward peer P/E

This model does not apply to this company with the available financial data.

P/E comparison

This model does not apply to this company with the available financial data.

PEG comparison

This model does not apply to this company with the available financial data.

Two-stage dividend discount

This model does not apply to this company with the available financial data.

Growing-dividend model

This model does not apply to this company with the available financial data.

REIT funds from operations

This model does not apply to this company with the available financial data.

Utility earnings

This model does not apply to this company with the available financial data.

Book value / net assets

This model does not apply to this company with the available financial data.

Reported crypto treasury NAV

This model does not apply to this company with the available financial data.

Proved-reserve NAV

This model does not apply to this company with the available financial data.

Model values are estimates under the assumptions shown. They are not share-price forecasts or investment advice.

Valuation models compared

Growth cash-flow modelRevenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged.
~$0.4~$0.2–$0.6
Forward price-to-sales vs peersNext year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative.
~$1.0~$1.1–$3.7
Models combinedweighted average of 3 models; primary model counts double
~$0.6~$0.4–$1.0

Different models answer different questions: the cash-flow models ask what the business generates for owners; the peer multiples ask what similar companies in our coverage trade on. Where they disagree, the gap is the story. Projections are estimates based on current data, updated daily. Not investment advice. How each model works.

Analyst recommendations

3 analysts, Oct 2026
Buy3100%
Hold00%
Sell00%

Monthly trend

  1. Oct 2026123
  2. Sep 2026112
  3. Aug 2026112

Counts of recommendations published by analysts covering Xtant Medical Holdings, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Price history

Loading chart…

Third-party market data · may be delayed

How our value has changed

Our value per share (re-run on each quarter's filings) Share price, month end
$1 $2 $3 2020202120222023202420252026
View the data
PeriodOur value per share
FY2019 Q2 (backtest)$1.89
FY2019 Q3 (backtest)$1.62
FY2019 Q4 (backtest)$2.89
FY2020 Q1 (backtest)$1.00
FY2020 Q2 (backtest)$1.07
FY2020 Q3 (backtest)$0.54
FY2020 Q4 (backtest)$3.65
FY2021 Q1 (backtest)$2.96
FY2021 Q4 (backtest)$0.09

Our model re-run on each past quarter's filed figures: how the method would have valued Xtant Medical Holdings, Inc. at the time (a backtest — our dated public record starts at launch). The grey line is the share price at month end, for comparison.

XTNT valuation questions

How does Fundamentalytics value Xtant Medical Holdings, Inc.?
We use the models that fit Xtant Medical Holdings, Inc.'s business and available financial data: growth cash-flow model, forward price-to-sales vs peers, revenue-to-maturity model. Each model has its own assumptions and data requirements. The calculator explains which models are available and lets you adjust their inputs.

Data: SEC EDGAR filings, retrieved October 29, 2026. Method: how we value companies. Disclosures: research and recommendations disclosure. Back to Xtant Medical Holdings, Inc.

Compare with peers